Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07222748

A Study of TLC590 for Postsurgical Pain Following Bunionectomy

This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local infiltration in adult subjects following bunionectomy.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Clinical Pharmacology of Miami, Miami, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able and willing to provide written informed consent.
  • Male or female aged 18 years or older (inclusive).
  • Scheduled to undergo a primary unilateral, transpositional first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia.
  • ASA Physical Status Classification of 1 or 2.
  • Male subjects must be either biologically or surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence.
  • Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, or committing to the use of a highly effective method of birth control.
  • BMI >18 ~ ≤39 kg/m2, with a minimum weight of 50 kg.

Exclusion criteria

  • An abnormal clinical laboratory test value.
  • Evidence of a clinically significant abnormal 12-lead ECG.
  • History of orthostatic hypotension, syncope, or other syncopal attacks.
  • History or any clinical manifestation of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other conditions that have been assessed by the Investigator to make the subject unsuitable for participation in the study.
  • History of seizures or taking anticonvulsants.
  • History of cardiac arrhythmia or taking Class III antiarrhythmic drugs.
  • History of sleep apnea or at-home CPAP treatment.
  • History of hypersensitivity to ropivacaine, bupivacaine, any other amide-type local anesthetic, or any other trial-required medications.
  • History of severe or refractory PONV due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer, deemed clinically significant by the Investigator.
  • Any lifetime history of a suicidal attempt or any suicidal behavior.
  • History or positive test results of HIV, HCV, or HBV.
  • History or current report of substance abuse including illicit drug abuse and/or alcohol abuse.
  • Positive results on the urine drug screen or alcohol breath test.
  • Pre-existing concurrent acute, or chronic painful restrictive/physical condition that may confound postoperative pain assessments or is expected to require analgesic treatment during the study.
  • Has known or suspected daily use of opioids for longer than 4 days per week within 6 months.
  • Use of daily analgesics for longer than 4 days per week for a chronically painful condition.
  • Is receiving oxygen therapy.
  • Use of any of the pre-specified medications prior to the study surgical procedure or as specified.
  • Malignancy in the past 2 years, except for non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Personal or family history of malignant hyperthermia.

Treatment and study plan

TLC590

Drug

TLC590 (Ropivacaine Extended-Release Injectable Suspension)

Liposomal bupivacaine

Drug

Bupivacaine Liposome Injectable Suspension

Saline placebo

Drug

Normal Saline 0.9%

Primary outcomes

  1. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Saline Placebo.

    Time frame: 72 hours

    Pain intensity is measured using an 11-point Numeric Rating Scale (NRS) (0-10), where 0 represents "no pain" and 10 represents "worst pain imaginable", and higher scores indicate worse pain.

Secondary outcomes

  1. Proportion of subjects who are opioid-free for TLC590 compared with Saline Placebo.

    Time frame: 72 hours

  2. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Bupivacaine Liposome.

    Time frame: 72 hours

    Pain intensity is measured using an 11-point Numeric Rating Scale (NRS) (0-10), where 0 represents "no pain" and 10 represents "worst pain imaginable", and higher scores indicate worse pain.

  3. Mean Total Postoperative Opioid Consumption for TLC590 Compared with Saline Placebo

    Time frame: 72 hours

  4. Proportion of subjects who are opioid-free for TLC590 compared with Bupivacaine Liposome.

    Time frame: 72 hours

  5. Mean Total Postoperative Opioid Consumption for TLC590 Compared with Bupivacaine Liposome.

    Time frame: 72 hours

Sponsors and collaborators

Lead sponsor

TLC Biopharmaceuticals, Inc.

Industry

Registry information

Official study title

A Phase 3, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety and Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 30, 2025
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.